
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6805612/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tyrosine Hydroxylase. Journal of Biological Chemistry, 1964, 239, 2910-2917.	3.4	1,867
2	Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neuroscience Letters, 1994, 165, 208-210.	2.1	884
3	Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the CTP cyclohydrolase I gene. Nature Genetics, 1994, 8, 236-242.	21.4	800
4	Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neuroscience Letters, 1994, 180, 147-150.	2.1	770
5	Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathologica, 2003, 106, 518-526.	7.7	619
6	Photometric Assay of Dopamine-β-Hydroxylase Activity in Human Blood. Clinical Chemistry, 1972, 18, 980-983.	3.2	513
7	A rapid and simple radioassay for tyrosine hydroxylase activity. Analytical Biochemistry, 1964, 9, 122-126.	2.4	505
8	Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neuroscience Letters, 1996, 211, 13-16.	2.1	496
9	The newly synthesized selective Ca2+calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochemical and Biophysical Research Communications, 1991, 181, 968-975.	2.1	473
10	Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nature Genetics, 2000, 26, 29-36.	21.4	388
11	Inflammatory Process in Parkinsons Disease: Role for Cytokines. Current Pharmaceutical Design, 2005, 11, 999-1016.	1.9	370
12	Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neuroscience Letters, 1999, 270, 45-48.	2.1	342
13	New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase. Analytical Biochemistry, 1976, 74, 466-476.	2.4	308
14	A Quantitative-Trait Analysis of Human Plasma–Dopamine β-Hydroxylase Activity: Evidence for a Major Functional Polymorphism at the DBH Locus. American Journal of Human Genetics, 2001, 68, 515-522.	6.2	253
15	Neuroprotective Effects of Glial Cell Line-Derived Neurotrophic Factor Mediated by an Adeno-Associated Virus Vector in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2002, 22, 6920-6928.	3.6	244
16	Highly sensitive assay for tyrosine hydroxylase activity by high-performance liquid chromatography. Biomedical Applications, 1979, 163, 247-252.	1.7	232
17	Isoquinoline neurotoxins in the brain and Parkinson's disease. Neuroscience Research, 1997, 29, 99-111.	1.9	231
18	p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain. Neuroscience Letters, 2007, 414, 94-97.	2.1	217

#	Article	IF	CITATIONS
19	Ablation of Cerebellar Golgi Cells Disrupts Synaptic Integration Involving GABA Inhibition and NMDA Receptor Activation in Motor Coordination. Cell, 1998, 95, 17-27.	28.9	210
20	An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neuroscience Letters, 1988, 87, 178-182.	2.1	207
21	Targeted Disruption of the Tyrosine Hydroxylase Locus Results in Severe Catecholamine Depletion and Perinatal Lethality in Mice. Journal of Biological Chemistry, 1995, 270, 27235-27243.	3.4	193
22	Expression of mRNAs for neuropeptide receptors and β-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neuroscience Letters, 1997, 233, 125-128.	2.1	191
23	Triple Transduction with Adeno-Associated Virus Vectors Expressing Tyrosine Hydroxylase, Aromatic-L-Amino-Acid Decarboxylase, and GTP Cyclohydrolase I for Gene Therapy of Parkinson's Disease. Human Gene Therapy, 2000, 11, 1509-1519.	2.7	191
24	Interleukin-10 Inhibits Both Production of Cytokines and Expression of Cytokine Receptors in Microglia. Journal of Neurochemistry, 2001, 72, 1466-1471.	3.9	188
25	Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in Parkinsonian and normal human brains. Biochemical and Biophysical Research Communications, 1987, 144, 1084-1089.	2.1	185
26	Behavioral Recovery in a Primate Model of Parkinson's Disease by Triple Transduction of Striatal Cells with Adeno-Associated Viral Vectors Expressing Dopamine-Synthesizing Enzymes. Human Gene Therapy, 2002, 13, 345-354.	2.7	182
27	Isolation of a novel cDNA clone for human tyrosine hydroxylase: Alternative RNA splicing produces four kinds of mRNA from a single gene. Biochemical and Biophysical Research Communications, 1987, 146, 971-975.	2.1	162
28	Human dopamine β-hydroxylase gene: two mRNA types having different 3'terminal regions are produced through alternative polyadenylation. Nucleic Acids Research, 1989, 17, 1089-1102.	14.5	158
29	Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neuroscience Letters, 1995, 193, 129-132.	2.1	157
30	Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenousl-DOPA in the rat, with reference to the involvement of aromaticl-amino acid decarâ~ylase. Brain Research, 1994, 667, 295-299.	2.2	153
31	Synaptic Integration Mediated by Striatal Cholinergic Interneurons in Basal Ganglia Function. Science, 2000, 289, 633-637.	12.6	151
32	L-dopa therapy for Parkinson's disease: Past, present, and future. Parkinsonism and Related Disorders, 2009, 15, S3-S8.	2.2	151
33	FUSARIC ACID, A HYPOTENSIVE AGENT PRODUCED BY FUNGI. Journal of Antibiotics, 1969, 22, 228-230.	2.0	143
34	Structure of the Human Tyrosine Hydroxylase Gene: Alternative Splicing from a Single Gene Accounts for Generation of Four mRNA Types1. Journal of Biochemistry, 1988, 103, 907-912.	1.7	139
35	Cytosolic Catechols Inhibit Â-Synuclein Aggregation and Facilitate the Formation of Intracellular Soluble Oligomeric Intermediates. Journal of Neuroscience, 2006, 26, 10068-10078.	3.6	135
36	Changes in Prolyl Endopeptidase During Maturation of Rat Brain and Hydrolysis of Substance P by the Purified Enzyme. Journal of Neurochemistry, 1980, 35, 527-535.	3.9	132

#	Article	IF	CITATIONS
37	Dopamine β-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Human Genetics, 1998, 102, 533-540.	3.8	127
38	A simple and sensitive assay for dopamine-β-hydroxylase activity by dual-wavelength spectrophotometry. Biochemical Medicine, 1974, 10, 320-328.	0.5	125
39	Catecholamines and Serotonin Are Differently Regulated by Tetrahydrobiopterin. Journal of Biological Chemistry, 2001, 276, 41150-41160.	3.4	124
40	Conversion of L-tyrosine to 3,4-dihydroxyphenylalanine by cell-free preparations of brain and sympathetically innervated tissues. Biochemical and Biophysical Research Communications, 1964, 14, 543-549.	2.1	121
41	Biopterin in human brain and urine from controls and parkinsonian patients: Application of a new radioimmunoassay. Clinica Chimica Acta, 1981, 109, 305-311.	1.1	121
42	Characterization of Mouse and Human GTP Cyclohydrolase I Genes. Journal of Biological Chemistry, 1995, 270, 10062-10071.	3.4	121
43	Tissue-specific and high-level expression of the human tyrosine hydroxylase gene in transgenic mice. Neuron, 1991, 6, 583-594.	8.1	120
44	Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathologica, 2005, 109, 141-150.	7.7	119
45	Behavioral Recovery in 6-Hydroxydopamine-Lesioned Rats by Cotransduction of Striatum with Tyrosine Hydroxylase and Aromatic <scp>l</scp> -Amino Acid Decarboxylase Genes Using Two Separate Adeno-Associated Virus Vectors. Human Gene Therapy, 1998, 9, 2527-2535.	2.7	113
46	A N-methyltransferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline into N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion. Biochemical and Biophysical Research Communications, 1989, 161, 1213-1219.	2.1	112
47	A new and highly sensitive voltammetric assay for aromatic l-amino acid decarboxylase activity by high-performance liquid chromatography. Analytical Biochemistry, 1979, 100, 160-165.	2.4	110
48	Progress in Monoamine Oxidase (MAO) Research in Relation to Genetic Engineering. NeuroToxicology, 2004, 25, 11-20.	3.0	106
49	Aromaticl-amino acid decarâ [~] ylase-immunoreactive neurons in and around the cerebrospinal fluid-contacting neurons of the central canal do not contain dopamine or serotonin in the mouse and rat spinal cord. Brain Research, 1988, 475, 91-102.	2.2	105
50	Isolation and characterization of a cDNA clone encoding human aromatic L-amino acid decarboxylase. Biochemical and Biophysical Research Communications, 1989, 164, 1024-1030.	2.1	105
51	N-Methylation of Dopamine-Derived 6,7-Dihydroxy-1,2,3,4-Tetrahydroisoquinoline, (R)-Salsolinol, in Rat Brains: In Vivo Microdialysis Study. Journal of Neurochemistry, 1992, 59, 395-400.	3.9	104
52	Human tyrosine hydroxylase in Parkinson's disease and in related disorders. Journal of Neural Transmission, 2019, 126, 397-409.	2.8	102
53	Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes. Neuroscience Letters, 1990, 119, 109-113.	2.1	101
54	Behavioral Recovery in 6-Hydroxydopamine-Lesioned Rats by Cotransduction of Striatum with Tyrosine Hydroxylase and Aromatic L-Amino Acid Decarboxylase Genes Using Two Separate Adeno-Associated Virus Vectors. Human Gene Therapy, 1998, 9, 2527-2535.	2.7	99

#	Article	IF	CITATIONS
55	Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains. Biochemical and Biophysical Research Communications, 1991, 177, 603-609.	2.1	98
56	Molecular cloning of genomic DNA and chromosomal assignment of the gene for human aromatic L-amino acid decarboxylase, the enzyme for catecholamine and serotonin biosynthesis. Biochemistry, 1992, 31, 2229-2238.	2.5	96
57	Oxidation of N-Methyl-1,2,3,4-Tetrahydroisoquinoline into the N-Methyl-Isoquinolinium Ion by Monoamine Oxidase. Journal of Neurochemistry, 1989, 52, 653-655.	3.9	95
58	Multiple mRNA forms of human GTP cyclohydrolase I. Biochemical and Biophysical Research Communications, 1992, 187, 359-365.	2.1	94
59	The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neuroscience Letters, 1996, 220, 195-198.	2.1	94
60	increased dopamine and serotonin metabolism in rat nucleus accumbens produced by intracranial self-stimulation of medial forebrain bundle as measured by in vivo microdialysis. Brain Research, 1989, 495, 178-181.	2.2	93
61	Stimulus-Coupled Interaction of Tyrosine Hydroxylase with 14-3-3 Proteinsâ€. Biochemistry, 1999, 38, 15673-15680.	2.5	93
62	Serum dopamine β-hydroxylase activity in developing hypertensive rats. Nature, 1974, 251, 630-631.	27.8	91
63	L-threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of Parkinsonism Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 1981, 57, 351-354.	3.8	90
64	Molecular Genetics of Dopa-Responsive Dystonia. Biological Chemistry, 1999, 380, 1355-64.	2.5	85
65	Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-α induction. Neuroscience Letters, 1999, 268, 101-104.	2.1	77
66	Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. Biomedical Applications, 1989, 493, 347-352.	1.7	76
67	Distribution of post-proline cleaving enzyme in human brain and the peripheral tissues. Molecular and Cellular Biochemistry, 1980, 32, 117-21.	3.1	75
68	Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy. Journal of Neural Transmission, 2002, 109, 731-745.	2.8	75
69	Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra?. Neuroscience Letters, 1998, 253, 198-200.	2.1	74
70	Inhibitory Action of Chlorpromazine on the Oxidation of D-Amino-Acid in the Diencephalon Part of the Brain. Nature, 1956, 177, 891-892.	27.8	72
71	Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene. Journal of Neuroscience Research, 2001, 65, 289-297.	2.9	71
72	Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects. Journal of Neural Transmission, 2016, 123, 1255-1278.	2.8	71

#	Article	IF	CITATIONS
73	Brain-specific gene expression by immortalized microglial cell-mediated gene transfer in the mammalian brain. FEBS Letters, 1998, 433, 37-40.	2.8	69
74	Tyrosine Hydroxylase Activity in Caudate Nucleus from Parkinson's Disease: Effects of Iron and Phosphorylating Agents. Journal of Neurochemistry, 1988, 50, 202-208.	3.9	66
75	Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1β and nerve growth factor in the striatum. Neuroscience Letters, 1998, 250, 25-28.	2.1	65
76	Determinants of cardiac noradrenaline depletion in human congestive failure. Cardiovascular Research, 1973, 7, 344-350.	3.8	63
77	Tissue-specific alternative splicing of the first exon generates two types of mRNAs in human aromatic L-amino acid decarboxylase. Biochemistry, 1992, 31, 11546-11550.	2.5	62
78	Modest Neuropsychological Deficits Caused by Reduced Noradrenaline Metabolism in Mice Heterozygous for a Mutated Tyrosine Hydroxylase Gene. Journal of Neuroscience, 2000, 20, 2418-2426.	3.6	59
79	Primary structure of mouse tyrosine hydroxylase deduced from its cDNA. Biochemical and Biophysical Research Communications, 1991, 176, 1610-1616.	2.1	58
80	Inhibition of Tyrosine Hydroxylase by R and S Enantiomers of Salsolinol, 1-Methyl-6,7-Dihydroxy-1,2,3,4- Tetrahydroisoquinoline. Journal of Neurochemistry, 1992, 58, 2097-2101.	3.9	56
81	Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain. Journal of the Neurological Sciences, 1992, 109, 219-223.	0.6	55
82	Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines. Journal of Neural Transmission, 2009, 116, 1355-1362.	2.8	55
83	Bradykininase activity of aloe extract. Biochemical Pharmacology, 1976, 25, 205.	4.4	54
84	Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography—mass spectrometry. Journal of Chromatography A, 1988, 452, 85-91.	3.7	52
85	Studies on Tyrosine Hydroxylase System in Rat Brain Slices Using High-Performance Liquid Chromatography with Electrochemical Detection. Journal of Neurochemistry, 1983, 40, 1585-1589.	3.9	50
86	The catecholamine system in health and disease -Relation to tyrosine 3-monooxygenase and other catecholamine-synthesizing enzymes Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2006, 82, 388-415.	3.8	49
87	Inhibition of tyrosine hydroxylation in tissue slices of the rat striatum by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Research, 1985, 337, 193-196.	2.2	47
88	The effects of pyridinium salts, structurally related compounds of 1-methyl-4-phenylpyridinium ion (MPP+), on tyrosine hydroxylation in rat striatal tissue slices. Brain Research, 1986, 397, 341-344.	2.2	44
89	Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase activity in vitro and tyrosine hydroxylase content. Neuroscience Letters, 1987, 80, 213-218.	2.1	43
90	Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission. Journal of Neuroscience Research, 1998, 54, 450-464.	2.9	43

#	Article	IF	CITATIONS
91	Characterization of Wild-Type and Mutants of Recombinant Human GTP Cyclohydrolase I. Journal of Neurochemistry, 2002, 73, 2510-2516.	3.9	43
92	Structure of the mouse tyrosine hydroxylase gene. Biochemical and Biophysical Research Communications, 1992, 182, 348-354.	2.1	42
93	Amine-related neurotoxins in Parkinson's disease. Neurotoxicology and Teratology, 2002, 24, 565-569.	2.4	40
94	Multiple mRNAs of monkey tyrosine hydroxylase. Biochemical and Biophysical Research Communications, 1990, 173, 1331-1336.	2.1	38
95	Dopamine Inhibition of Human Tyrosine Hydroxylase Type 1 Is Controlled by the Specific Portion in the N-Terminus of the Enzyme. Journal of Neurochemistry, 2008, 72, 2145-2153.	3.9	36
96	Early and late effects of systemically administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on tyrosine hydroxylase activity in vitro and on tyrosine hydroxylation in tissue slices of mouse striatum. Neuroscience Letters, 1986, 68, 245-248.	2.1	35
97	Detection of tetrahydroisoquinoline in parkinsonian brain as an endogenous amine by use of gas chromatography-mass spectrometry. Biomedical Applications, 1989, 491, 397-403.	1.7	35
98	Analysis of the Alternative Promoters that Regulate Tissue-Specific Expression of Human Aromatic l-Amino Acid Decarboxylase. Journal of Neurochemistry, 2002, 64, 514-524.	3.9	35
99	Separation of Two Dipeptidyl Aminopeptidases in the Human Brain. Journal of Neurochemistry, 1980, 34, 602-608.	3.9	34
100	Inhibition of tyrosine hydroxylation in rat striatal tissue slices by 1-methyl-4-phenylpyridinium ion. Neuroscience Letters, 1985, 57, 301-305.	2.1	34
101	Coexpression of GTP cyclohydrolase I and inducible nitric oxide synthase mRNAs in mouse osteoblastic cells activated by proinflammatory cytokines. FEBS Letters, 1998, 428, 212-216.	2.8	34
102	Highly Sensitive Assay for Dopamine-?-Hydroxylase Activity in Human Cerebrospinal Fluid by High Performance Liquid Chromatography-Electrochemical Detection: Properties of the Enzyme. Journal of Neurochemistry, 1981, 37, 289-296.	3.9	33
103	A sensitive and specific assay for dipeptidyl-aminopeptidase II in serum and tissues by liquid chromatography-fluorometry. Analytical Biochemistry, 1985, 147, 80-85.	2.4	33
104	Identification of 5-S- and 2-S-cysteinyldopamine and 5-S-glutathionyldopamine formed from dopamine by high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1986, 375, 134-140.	1.7	32
105	Inhibition of Monoamine Oxidase by N-Methylisoquinolinium Ion. Journal of Neurochemistry, 1987, 48, 709-712.	3.9	32
106	Molecular biology of catecholamine-related enzymes in relation to Parkinson's disease. Cellular and Molecular Neurobiology, 1999, 19, 57-66.	3.3	32
107	Molecular genetics of tyrosine 3-monooxygenase and inherited diseases. Biochemical and Biophysical Research Communications, 2005, 338, 267-270.	2.1	32
108	Neuromelanin in Parkinson's Disease: Tyrosine Hydroxylase and Tyrosinase. International Journal of Molecular Sciences, 2022, 23, 4176.	4.1	32

#	Article	IF	CITATIONS
109	Prevention of dopaminergic neuron death by adeno-associated virus vector-mediated GDNF gene transfer in rat mesencephalic cells in vitro. Neuroscience Letters, 1998, 248, 61-64.	2.1	31
110	Phosphorylation of the N-terminal portion of tyrosine hydroxylase triggers proteasomal digestion of the enzyme. Biochemical and Biophysical Research Communications, 2011, 407, 343-347.	2.1	31
111	Effects of Systemic Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine to Mice on Tyrosine Hydroxylase, I-3,4-Dihydroxyphenylalanine Decarboxylase, Dopamine ?-Hydroxylase, and Monoamine Oxidase Activities in the Striatum and Hypothalamus. Journal of Neurochemistry, 1988, 50, 1053-1056.	3.9	29
112	Complex Formation of Chlorpromazine with Flavins. Nature, 1959, 184, 982-983.	27.8	27
113	Endogenous synthesis of N-methylsalsolinol, an analogue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in rat brain during in vivo microdialysis with salsolinol, as demonstrated by gas chromatography—mass spectrometry. Biomedical Applications, 1992, 578, 109-115.	1.7	27
114	Inactivation of tyrosine hydroxylase in rat striatum by 1-methyl-4-phenylpyridinium ion (MPP+). Neuroscience Letters, 1988, 85, 228-232.	2.1	26
115	A possible pathophysiological role of tyrosine hydroxylase in Parkinson's disease suggested by postmortem brain biochemistry: a contribution for the special 70th birthday symposium in honor of Prof. Peter Riederer. Journal of Neural Transmission, 2013, 120, 49-54.	2.8	26
116	The mutation of two amino acid residues in the N-terminus of tyrosine hydroxylase (TH) dramatically enhances the catalytic activity in neuroendocrine AtT-20 cells. Journal of Neurochemistry, 2002, 82, 202-206.	3.9	23
117	β2-microglobulin decrease in cerebrospinal fluid from parkinsonian patients. Neuroscience Letters, 1989, 104, 241-246.	2.1	22
118	Inhibition of type A monoamine oxidase by 1-methyl-4-phenylpyridine. Neuroscience Letters, 1987, 73, 293-297.	2.1	21
119	Analysis of salsolinol in human brain using high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1988, 428, 152-155.	1.7	21
120	Characterization of four new cell lines derived from small-cell gastrointestinal carcinoma. International Journal of Cancer, 1993, 54, 965-971.	5.1	21
121	Dopamine-β-hydroxylase in blood and cerebrospinal fluid. Trends in Biochemical Sciences, 1977, 2, 217-219.	7.5	20
122	Purification of dipeptidyl-aminopeptidase IV from human kidney by anti dipeptidyl-aminopeptidase IV affinity chromatography. Molecular and Cellular Biochemistry, 1982, 43, 35-42.	3.1	20
123	Mechanism of antiinflammatory and antithermal burn action of CPase fromAloe arborescens Miller var.natalensis Berger in rats and mice. Phytotherapy Research, 1993, 7, S30-S33.	5.8	20
124	Inhibition of deubiquitinating activity of USP14 decreases tyrosine hydroxylase phosphorylated at Ser19 in PC12D cells. Biochemical and Biophysical Research Communications, 2016, 472, 598-602.	2.1	20
125	Tetrahydrobiopterin administration for Parkinsonian symptoms Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 1982, 58, 283-287.	3.8	19
126	Biochemical properties of carboxypeptidase fromAloe arborescens Miller var.natalensis Berger. Phytotherapy Research, 1993, 7, S26-S29.	5.8	18

#	Article	IF	CITATIONS
127	Inhibition of azoxymethane-induced aberrant crypt foci formation in rat colorectum by whole leafAloe arborescens Miller var.natalensis berger. Phytotherapy Research, 2001, 15, 705-711.	5.8	18
128	Dipeptidyl-aminopeptidase II in human cerebrospinal fluid: Changes in patients with Parkinson's disease. Biochemical Medicine and Metabolic Biology, 1987, 37, 360-365.	0.7	16
129	Characterization of the human NTAK gene structure and distribution of the isoforms for rat NTAK mRNA. Gene, 2000, 255, 15-24.	2.2	16
130	INCORPORATION OF PERIPHERALLY ADMINISTERED RIBOFLAVINE INTO FLAVINE NUCLEOTIDES IN THE BRAIN. Journal of Neurochemistry, 1967, 14, 207-210.	3.9	15
131	Effects of dopamine on N-terminus-deleted human tyrosine hydroxylase type 1 expressed in Escherichia coli. Neuroscience Letters, 1997, 229, 57-60.	2.1	15
132	A new splicing variant for human tyrosine hydroxylase in the adrenal medulla. Neuroscience Letters, 2001, 312, 157-160.	2.1	15
133	Intracellular Stability of Tyrosine Hydroxylase. Advances in Pharmacology, 2013, 68, 3-11.	2.0	15
134	Post-proline cleaving enzyme in human cerebrospinal fluid from control patients and parkinsonian patients. Biochemical Medicine and Metabolic Biology, 1987, 38, 387-391.	0.7	14
135	Ganglioside GM1 Causes Expression of Type B Monoamine Oxidase in a Rat Clonal Pheochromocytoma Cell Line, PC12h. Journal of Neurochemistry, 1987, 49, 1602-1605.	3.9	14
136	Characterization of neuron-specific huntingtin aggregates in human huntingtin knock-in mice. Neuroscience Research, 2007, 57, 559-573.	1.9	14
137	Effect of the 1-methyl-4-phenylpyridinium ion on phosphorylation of tyrosine hydroxylase in rat pheochromocytoma PC12h cells. Neuroscience Letters, 1988, 89, 209-215.	2.1	13
138	Peripherally administered (6R)-tetrahydrobiopterin increases in vivo tyrosine hydroxylase activity in the striatum measured by microdialysis both in normal mice and in transgenic mice carrying human tyrosine hydroxylase. Neuroscience Letters, 1994, 182, 44-46.	2.1	13
139	Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects. Journal of Neural Transmission, 2017, 124, 739-744.	2.8	13
140	Inhibition of Type A Monoamine Oxidase by Methylquinolines and Structurally Related Compounds. Journal of Neurochemistry, 1988, 50, 1105-1110.	3.9	12
141	Sandwich enzyme immunoassay of dopamine-î²-hydroxylase in cerebrospinal fluid from control and parkinsonian patients. Neurochemistry International, 1988, 12, 187-191.	3.8	12
142	Endogenous synthesis of N-methylnorsalsolinol in rat brain during in vivo microdialysis with epinine. Biomedical Applications, 1994, 654, 263-269.	1.7	12
143	Autonomic neuropathy in transgenic mice caused by immunotoxin targeting of the peripheral nervous system. , 1998, 51, 162-173.		12
144	Direct imaging of phosphorylation-dependent conformational change and DNA binding of CREB by electron microscopy. Genes To Cells, 2000, 5, 515-522.	1.2	12

#	Article	IF	CITATIONS
145	Positive charge intrinsic to Arg37-Arg38is critical for dopamine inhibition of the catalytic activity of human tyrosine hydroxylase type 1. FEBS Letters, 2000, 465, 59-63.	2.8	12
146	Identification by nano-LC-MS/MS of NT5DC2 as a protein binding to tyrosine hydroxylase: Down-regulation of NT5DC2 by siRNA increases catecholamine synthesis in PC12D cells. Biochemical and Biophysical Research Communications, 2019, 516, 1060-1065.	2.1	12
147	Dopamine-β-hydroxylase and tyrosine hydroxylase activities in brain regions of rolling mouse <i>Nagoya </i> . Biomedical Research, 1980, 1, 88-90.	0.9	12
148	Purification and Properties of Bovine Brain Dopamine ?-Hydroxylase. Journal of Neurochemistry, 1982, 39, 1066-1071.	3.9	11
149	Effect of long-term administration of 1,2,3,4-tetrahydroisoquinoline (TIQ) on striatal dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) content in mice. Neuroscience Letters, 1988, 92, 321-324.	2.1	11
150	Establishment of a Human Small Cell Lung Cancer Cell Line Producing a Large Amount of Anti-diuretic Hormone. Japanese Journal of Cancer Research, 1994, 85, 718-722.	1.7	11
151	Detection of 1-phenyl-N-methyl-1,2,3,4-tetrahydroisoquinoline and 1-phenyl-1,2,3,4-tetrahydroisoquinoline in human brain by gas chromatography—tandem mass spectrometry. Biomedical Applications, 1995, 669, 345-351.	1.7	11
152	RNAi of 14-3-3î∙ protein increases intracellular stability of tyrosine hydroxylase. Biochemical and Biophysical Research Communications, 2007, 363, 817-821.	2.1	11
153	Presence of N-methyldopamine in parkinsonian and normal human brains. Biomedical Applications, 1993, 613, 1-8.	1.7	10
154	Identification of (6R)-5,6,7,8-Tetrahydro-D-monapterin (=(6R)-2-Amino-5,6,7,8-tetrahydro-6-[(1R,2R)-1,2,3) Tj ET Chimica Acta, 2001, 84, 918-927.	Qq0 0 0 rg 1.6	gBT /Overlock 10
155	Deletion of N-terminus of human tyrosine hydroxylase type 1 enhances stability of the enzyme in AtT-20 cells. Journal of Neuroscience Research, 2005, 81, 110-120.	2.9	10
156	IMMUNOHISTOCYTOCHEMICAL DISTRIBUTION OF AMINE-CONTAINING NEURONS RELATED TO CIRCUMVENTRICULAR ORGANS IN THE FROG BRAIN . Biomedical Research, 1982, 3, 623-636.	0.9	10
157	IMMUNOHISTOCHEMICAL LOCALIZATION OF CATECHOLAMINE SYNTHESIZING ENZYMES IN BULLFROG ADRENALS. Acta Histochemica Et Cytochemica, 1979, 12, 416-422.	1.6	8
158	Simple Photometric Assay of Dopamine-β-Hydroxylase Activity in Human Blood: Useful in Clinical Chemistry. Clinical Chemistry, 2009, 55, 193-194.	3.2	8
159	Tyrosine Hydroxylase. , 2012, , 45-47.		8
160	NT5DC2 affects the phosphorylation of tyrosine hydroxylase regulating its catalytic activity. Journal of Neural Transmission, 2020, 127, 1631-1640.	2.8	8
161	Condensation Products of Ethylenediamine with Adrenaline. Nature, 1959, 183, 822-824.	27.8	7
162	Immunohistocytochemical studies on neurons in hamster area postrema Acta Histochemica Et Cytochemica, 1983, 16, 138-147.	1.6	6

#	Article	IF	CITATIONS
163	Assignment of A and B Types of Monoamine Oxidase in NCB20 Hybrid Cells to Those of the Parental Cells by Peptide Mapping. Journal of Neurochemistry, 1986, 46, 686-694.	3.9	6
164	In memory of Professor Leonor Michaelis in Nagoya: Great contributions to biochemistry in Japan in the first half of the 20th century. FEBS Letters, 2013, 587, 2721-2724.	2.8	6
165	EFFECTS OF FLAVINS ON THE ELECTROENCEPHALOGRAM. Journal of Neurochemistry, 1959, 4, 229-233.	3.9	5
166	Hypothesis: neural mechanism of psychotherapy for the treatment of Parkinson's disease: cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy?. Journal of Neural Transmission, 2020, 127, 273-276.	2.8	5
167	Involvement of β₁-adrenergic receptors in regulation of the phosphorylation state of rat parotid gland proteins . Biomedical Research, 1984, 5, 77-82.	0.9	4
168	Formation of Noradrenaline from Adrenaline by Rat Liver Mitochondria. Nature, 1959, 184, 1316-1317.	27.8	3
169	Identification of the Main Ethylenediamine Condensate of Noradrenaline with that of Catechol. Nature, 1962, 193, 484-485.	27.8	3
170	Presence of endogenous inhibitor of aromatic L-amino acid decarboxylase in monkey serum. Molecular and Cellular Biochemistry, 1984, 63, 53-8.	3.1	3
171	Effect of Chronic Administration of 1,2,3,4-Tetrahydroisoquinoline and Its Derivatives on the Monkey: Immunohistochemical Study. Advances in Behavioral Biology, 1995, , 583-587.	0.2	3
172	IMMUNOHISTOCYTOCHEMICAL AND BIOCHEMICAL STUDIES ON CATECHOLAMINE-SYNTHESIZING ENZYMES OF THE LUMBAR SYMPATHETIC GANGLIA AND SCIATIC NERVES OF BULLFROGS . Biomedical Research, 1982, 3, 197-206.	0.9	3
173	MULTIPLE FORMS OF GLYCYLPROLYL DIPEPTIDYL AMINOPEPTIDASE (DIPEPTIDYL PEPTIDASE IV) IN HUMAN SERA FROM PATIENTS WITH HEPATITIS . Biomedical Research, 1982, 3, 265-269.	0.9	3
174	Cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy (MT); comparison of three established psychotherapies and possible common neural mechanisms of psychotherapies. Journal of Neural Transmission, 2022, 129, 805-828.	2.8	3
175	Changes of Quantity of Flavin in the Brain after Peripheral Administration of Flavins. Nature, 1961, 190, 728-728.	27.8	2
176	Genomic Organization of Mouse and Human GTP Cyclohydrolase I Genes and Mutations Found in the Human Gene. Pteridines, 1995, 6, 104-107.	0.5	2
177	The phosphorylation of Ser40 of tyrosine hydroxylase has no effect on the stability of the enzyme in PC12 cells. Biogenic Amines, 2005, 19, 279-288.	0.3	1
178	Endogenous MPTP-Like Amines in the Brain: Isoquinolines. , 1994, , 149-159.		1
179	Glycyl-prolyl-p-nitroanilidase (GPNAase) Activity in Cardiovascular Diseases. International Heart Journal, 1979, 20, 469-475.	0.6	1
180	Abnormality in Catecholamine Metabolism in the Brain of Spontaneously Hypertensive Rats (SHR). International Heart Journal, 1984, 25, 820-822.	0.6	1

#	Article	IF	CITATIONS
181	Identification of the Main Ethylene-diamine Condensate of Noradrenaline with that of Catechol. Nature, 1962, 194, 684-684.	27.8	0
182	Migration of Injected C ¹⁴ -labelled Riboflavin into Rat Tissues. Journal of Biochemistry, 1966, , .	1.7	0
183	Marshall Nirenberg (1927-2010) - Nobel Laureate, Giant of Neurochemistry and Molecular Biology, and Honorary Member of Japan Society for Neurochemistry. Journal of Neurochemistry, 2010, 113, no-no.	3.9	0
184	Isoquinoline Neurotoxins. , 2000, , 69-76.		0
185	Dopamine Neurons are Not Affected by Expanded Polyglutamine Stretches in HD Gene Knock-In Mice. Advances in Behavioral Biology, 2002, , 99-102.	0.2	0
186	Cytokines and Neurotrophins in Parkinson's Disease: Involvement in Apoptosis. Advances in Behavioral Biology, 2002, , 265-270.	0.2	0
187	Molecular Genetics of Catecholamines: Key Molecules Bridging Basic Science with Clinical Science. Advances in Behavioral Biology, 2002, , 5-17.	0.2	0
188	Monoamine Oxidase Inhibitor (MAO-I)-Mediated Neuroprotection for Treating Parkinson's Disease. , 2020, , 1-21.		0
189	Peter Riederer, a translational neurobiochemist. Journal of Neural Transmission, 2022, , 1.	2.8	0